clinical trial · NCT02819843
A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors
MelanomaMerkel Cell CarcinomaOther Solid TumorsTALIMOGENE LAHERPAREPVEC (TVEC)Hypofractionated Radiotherapy
brief summary
The purpose of this phase II clinical study is to test the good and bad effects of T-VEC (talimogene laherparepvec) with or without hypofractionated radiotherapy on people with melanoma, Merkel cell carcinoma, or other solid tumors with skin metastasis.
started
Jun 21, 2016
primary completion
Feb 22, 2024
completion
Feb 22, 2024
last updated
Jan 29, 2025
official title
A Phase II Randomized Trial of Intralesional Talimogene Laherparepvec (TALIMOGENE LAHERPAREPVEC) With or Without Radiotherapy for Cutaneous Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol